Trial reportDigestive diseases and sciences2005
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Trial report in Digestive diseases and sciences, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.Neurogastroenterology and motility · 2023Pooled it
- Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.World journal of gastroenterology · 2013Pooled it
- Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.The Cochrane database of systematic reviews · 2013Pooled it
- Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease.Alimentary pharmacology & therapeutics · 2010Pooled it
- Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.Digestive diseases and sciences · 2010Trial
- Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.Journal of gastroenterology · 2008Trial
- Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic-Pharmacodynamic Modeling.Biomedicines · 2023Article
- Belching in Gastroesophageal Reflux Disease: Literature Review.Journal of clinical medicine · 2020Review
- Chronic Burping and Belching.Current treatment options in gastroenterology · 2020Review
- The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.Scientific reports · 2016Article
- The Therapeutic and Diagnostic Value of 2-week High Dose Proton Pump Inhibitor Treatment in Overlapping Non-erosive Gastroesophageal Reflux Disease and Functional Dyspepsia Patients.Journal of neurogastroenterology and motility · 2012Article
- GERD: are functional heartburn and functional dyspepsia one disorder?Nature reviews. Gastroenterology & hepatology · 2010Article
- Nonerosive Reflux Disease (NERD) - An Update.Journal of neurogastroenterology and motility · 2010Article
- Body mass index and the efficacy of acid-mediating agents for GERD.Digestive diseases and sciences · 2008Review
- A review of rabeprazole in the treatment of acid-related diseases.Therapeutics and clinical risk management · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P < or = .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P < or = .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P < or = .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.